about
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.The NPM1 mutation type has no impact on survival in cytogenetically normal AML.FHL2 interacts with CALM and is highly expressed in acute erythroid leukemia.Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantationIn-depth mutational analyses of colorectal neuroendocrine carcinomas with adenoma or adenocarcinoma components.Close correlation of copy number aberrations detected by next-generation sequencing with results from routine cytogenetics in acute myeloid leukemia.Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4.Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosisUp a lymphoid blind alley: Does CALM/AF10 disturb Ikaros during leukemogenesis?The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor.Mutational landscape of adult ETP-ALL.FAT1 expression and mutations in adult acute lymphoblastic leukemia.ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation.Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.The target landscape of clinical kinase drugs.Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.Evolution of cytogenetically normal acute myeloid leukemia during therapy and relapse: An exome sequencing study of 50 patients.Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients.Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N terminus.The target cell of transformation is distinct from the leukemia stem cell in murine CALM/AF10 leukemia models.The CATS (FAM64A) protein is a substrate of the Kinase Interacting Stathmin (KIS).Clonal heterogeneity of -ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemiaCoexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AMLRelapse of acute myeloid leukemia after allogeneic stem cell transplantation is associated with gain of WT1 alterations and high mutation loadZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cellsCompatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansionGATA2 mutations in myeloid malignancies: Two zinc fingers in many piesPAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemiaThe clinical mutatome of core binding factor leukemiaAllelic Imbalance of Recurrently Mutated Genes in Acute Myeloid LeukaemiaLoss of KDM6A confers drug resistance in acute myeloid leukemiaClonal evolution of acute myeloid leukemia from diagnosis to relapse
P50
Q27853390-2A36E7C2-7DD7-4D4C-9157-EF8AF3E1D83CQ30313288-083AFD69-2B05-4610-B8F8-934289C55E79Q34315531-D3CFAAB9-BF92-4ADE-B951-01A30600CADAQ35668394-DF323274-35D5-42DD-AA56-9A309C5CDFE9Q35881417-064E0A68-ECBA-4A36-B619-F11F2E8C2BCDQ39430735-2EA09734-FCA3-438B-81B5-6B0F698DC6E8Q39888679-15D5C96B-A5AE-4A0C-BBCB-FA0D434D2EBFQ40519126-93A2FC3A-475B-4C2C-9CA2-7FBA7C7FFFFFQ40607280-E24007C3-879C-4B77-8458-D1A9A63AECACQ41866183-D8D56C79-6D6C-490F-A5A0-3C0E676E0CA5Q42534044-08C74481-0766-4774-8BE2-4B9503B9A901Q42580357-B0CA0692-1482-476E-9CA8-13056483BFDFQ42719018-772B665E-B924-48A9-B0E4-67BE64E12F9BQ42739123-0D88C81D-BBFB-47C1-A961-E07F5659372FQ43994207-F7D86F86-39D0-4957-B978-9454AE0C5ED6Q47307310-09D533CE-291D-4B51-B875-799FFBEBACF4Q47345032-4962CDA5-BCF6-4213-9DD7-20EEE4DAA0E0Q47818563-A38E6933-B711-4198-B718-3E0EFC3F67E2Q50059467-D75C697F-DF79-4404-83F4-CAEC0F68B7F7Q51069278-BABCF3BC-186A-4C36-8A6B-BDD054609AC6Q51336698-C554C59D-0DB1-44C9-A093-E9ABD2491DC5Q51599957-BFFE8567-4E6A-478F-A742-4268E4070E6BQ53119727-C0F64C64-4040-4FCF-A333-D2D332CFF15BQ56968572-D84C2F93-CED0-4B31-BD95-F6DC40F7542EQ57898900-F8F283DC-52AC-4C6E-B9A4-E81418E9EFAFQ57898906-942C7A00-1FE4-434B-A1AC-A73D06CDAFF7Q89960665-B9AE9701-FE16-401E-A061-19297AA0D271Q90859356-25B7528D-E6BF-4186-9B61-DA1BF4E9469DQ91563270-39A13359-8899-45DB-A774-D55BFED4FEFCQ92179595-24DBE90B-1F56-4D24-9511-20C263B31248Q92380929-8B58A1DD-0525-4D50-A192-D0CE94F2C74DQ92602708-CD3D6102-D99B-4738-81D0-6652739B976AQ92761572-781605B5-92AF-4ABD-87BD-B4EC94388B1BQ93067058-9C1CA5F6-77A8-4879-88B3-6CB47E15A315
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Philipp A Greif
@en
Philipp A Greif
@nl
type
label
Philipp A Greif
@en
Philipp A Greif
@nl
prefLabel
Philipp A Greif
@en
Philipp A Greif
@nl
P31
P496
0000-0002-3744-7936